JP2023544211A5 - - Google Patents
Info
- Publication number
- JP2023544211A5 JP2023544211A5 JP2023521536A JP2023521536A JP2023544211A5 JP 2023544211 A5 JP2023544211 A5 JP 2023544211A5 JP 2023521536 A JP2023521536 A JP 2023521536A JP 2023521536 A JP2023521536 A JP 2023521536A JP 2023544211 A5 JP2023544211 A5 JP 2023544211A5
- Authority
- JP
- Japan
- Prior art keywords
- nanocage
- monomer
- cov
- sars
- fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089782P | 2020-10-09 | 2020-10-09 | |
| US63/089,782 | 2020-10-09 | ||
| US202163197236P | 2021-06-04 | 2021-06-04 | |
| US63/197,236 | 2021-06-04 | ||
| US202163220929P | 2021-07-12 | 2021-07-12 | |
| US63/220,929 | 2021-07-12 | ||
| PCT/CA2021/051426 WO2022073138A1 (en) | 2020-10-09 | 2021-10-08 | Polypeptides targeting sars-cov-2 and related compositions and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023544211A JP2023544211A (ja) | 2023-10-20 |
| JP2023544211A5 true JP2023544211A5 (enExample) | 2024-10-17 |
Family
ID=81126329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023521536A Pending JP2023544211A (ja) | 2020-10-09 | 2021-10-08 | Ｓａｒｓ－ｃｏｖ－２を標的とするポリペプチドならびに関連する組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250263469A1 (enExample) |
| EP (1) | EP4225804A4 (enExample) |
| JP (1) | JP2023544211A (enExample) |
| KR (1) | KR20230083316A (enExample) |
| AU (1) | AU2021356355A1 (enExample) |
| BR (1) | BR112023006497A2 (enExample) |
| CA (1) | CA3197642A1 (enExample) |
| MX (1) | MX2023004023A (enExample) |
| WO (1) | WO2022073138A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117157328A (zh) * | 2021-01-28 | 2023-12-01 | 儿童医院 | Multabody构建体、组合物和方法 |
| EP4370558A4 (en) * | 2021-07-12 | 2025-09-10 | Hospital For Sick Children | OPTIMIZED MULTIBODY CONSTRUCTS, COMPOSITIONS AND METHODS |
| EP4605437A1 (en) * | 2022-10-21 | 2025-08-27 | The Hospital For Sick Children | Multabody constructs, compositions, and methods targeting sarbecoviruses |
| KR102946895B1 (ko) | 2022-10-21 | 2026-04-02 | 충남대학교산학협력단 | SARS-CoV-2 S1 유래 단백질 및 항체 Fc 영역 단백질을 표면에 동시에 디스플레이하는 페리틴 단백질 구조체 및 이의 코로나바이러스 SARS-CoV-2에 대한 백신 용도 |
| KR102969172B1 (ko) * | 2023-12-22 | 2026-05-26 | 연세대학교 산학협력단 | 펩타이드, 핵산, 재조합 발현 벡터, 세포, SARS-CoV-2용 백신 물질, SARS-CoV-2용 백신 조성물, 및 SARS-CoV-2 면역화 방법 |
| WO2025231346A1 (en) * | 2024-05-03 | 2025-11-06 | The Wistar Institute Of Anatomy And Biology | Anti-interferon-alpha and anti-interferon-beta antibodies, and methods of use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2780221A1 (en) * | 2009-11-04 | 2011-05-12 | Fabrus Llc | Methods for affinity maturation-based antibody optimization |
| SG11201408530YA (en) * | 2012-08-02 | 2015-03-30 | Hoffmann La Roche | Method for producing monomeric and multimeric molecules and uses thereof |
| WO2015109212A1 (en) * | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
| PT3215528T (pt) * | 2014-11-06 | 2019-10-11 | Hoffmann La Roche | Variantes da região fc com ligação modificada ao fcrn e métodos de utilização |
| WO2017196847A1 (en) * | 2016-05-10 | 2017-11-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens |
| CA3031194A1 (en) * | 2016-07-22 | 2018-01-25 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
| CA3071922A1 (en) * | 2017-08-04 | 2019-02-07 | The Governing Council Of The University Of Toronto | Nanoparticle platform for antibody and vaccine delivery |
| CR20220552A (es) * | 2020-04-02 | 2023-01-17 | Regeneron Pharma | Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno |
| CN111592595B (zh) * | 2020-04-27 | 2021-02-19 | 南京医科大学 | 抗新型冠状病毒SARS-Cov-2的中和性抗体及其应用 |
-
2021
- 2021-10-08 MX MX2023004023A patent/MX2023004023A/es unknown
- 2021-10-08 JP JP2023521536A patent/JP2023544211A/ja active Pending
- 2021-10-08 EP EP21876827.3A patent/EP4225804A4/en active Pending
- 2021-10-08 AU AU2021356355A patent/AU2021356355A1/en active Pending
- 2021-10-08 WO PCT/CA2021/051426 patent/WO2022073138A1/en not_active Ceased
- 2021-10-08 KR KR1020237015177A patent/KR20230083316A/ko active Pending
- 2021-10-08 US US18/030,944 patent/US20250263469A1/en active Pending
- 2021-10-08 CA CA3197642A patent/CA3197642A1/en active Pending
- 2021-10-08 BR BR112023006497A patent/BR112023006497A2/pt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4011914B2 (ja) | キメラポリペプチド、その製造方法、およびその使用 | |
| US10590196B2 (en) | Antibodies targeting G-protein coupled receptor and methods of use | |
| CN109641046A (zh) | 单链可变片段cd3结合蛋白质 | |
| JP2023504914A5 (enExample) | ||
| JP2023548443A5 (enExample) | ||
| US20170210818A1 (en) | Constant region antibody fusion proteins and compositions thereof | |
| JP2020517287A5 (enExample) | ||
| JP2020505919A5 (enExample) | ||
| JP2023509212A5 (enExample) | ||
| JP2023058590A5 (enExample) | ||
| JP2018502050A5 (enExample) | ||
| JP2021512159A5 (enExample) | ||
| NZ717476A (en) | Anti-garp protein and uses thereof | |
| CN109071654A (zh) | 靶向Fc受体样5的抗体及使用方法 | |
| JP2018515085A5 (enExample) | ||
| CN110234355A (zh) | 单体人IgG1 Fc和双特异性抗体 | |
| KR20120089863A (ko) | “개선된 당화반응 최종 생성물에 대한 수용체”에 결합하기 위한 폴리펩타이드 및 이를 포함하는 조성물 및 방법 | |
| JP2024504777A5 (enExample) | ||
| JP2012529891A5 (enExample) | ||
| JP2019506140A5 (enExample) | ||
| EP0617706A1 (en) | Multivalent antigen-binding proteins | |
| CN116925215A (zh) | 抗血清白蛋白纳米抗体及其衍生物 | |
| JP2024507540A5 (enExample) | ||
| JP2026004299A5 (enExample) | ||
| JP2019505565A5 (enExample) |